Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(1.95)
# 3,250
Out of 5,182 analysts
114
Total ratings
29.66%
Success rate
-4.79%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RANI Rani Therapeutics Holdings | Reiterates: Buy | $11 | $0.82 | +1,245.40% | 5 | Mar 27, 2026 | |
| DERM Journey Medical | Reiterates: Buy | $13 | $4.95 | +162.63% | 3 | Mar 26, 2026 | |
| ACHV Achieve Life Sciences | Reiterates: Buy | $12 | $3.20 | +275.00% | 3 | Mar 25, 2026 | |
| COLL Collegium Pharmaceutical | Reiterates: Buy | $60 | $32.76 | +83.15% | 9 | Mar 20, 2026 | |
| PTHS Pelthos Therapeutics | Reiterates: Buy | $60 | $22.74 | +163.85% | 2 | Mar 19, 2026 | |
| EPRX Eupraxia Pharmaceuticals | Maintains: Buy | $12 → $11 | $6.77 | +62.48% | 5 | Mar 17, 2026 | |
| SGMT Sagimet Biosciences | Reiterates: Buy | $29 | $5.08 | +470.87% | 3 | Mar 11, 2026 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $21 | $13.10 | +60.31% | 4 | Mar 9, 2026 | |
| XERS Xeris Biopharma Holdings | Reiterates: Buy | $10 | $5.87 | +70.36% | 5 | Mar 2, 2026 | |
| MNKD MannKind | Maintains: Buy | $11 → $8 | $2.57 | +211.28% | 9 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $4.10 | +217.07% | 5 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $1.40 | +542.86% | 3 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $13.43 | +48.92% | 3 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $13 | $7.17 | +81.31% | 5 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $0.79 | +660.07% | 3 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $40 | $10.98 | +264.30% | 4 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $1.61 | +396.89% | 4 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.60 | +400.00% | 1 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.58 | +532.91% | 1 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $93 → $121 | $79.47 | +52.26% | 6 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $5.95 | +202.52% | 2 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $2.82 | +148.23% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $9.68 | +168.60% | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $0.95 | +426.43% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $1.64 | +12,095.12% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $7.85 | +103.82% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $7.02 | +6,381.48% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $16.83 | +250.56% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $190.94 | -5.73% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $220 | $2.48 | +8,770.97% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $33.02 | -3.09% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $0.80 | +2,749,900.00% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 → $315 | $9.60 | +3,181.25% | 3 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $9.26 | +439.96% | 1 | Jul 12, 2018 |
Rani Therapeutics Holdings
Mar 27, 2026
Reiterates: Buy
Price Target: $11
Current: $0.82
Upside: +1,245.40%
Journey Medical
Mar 26, 2026
Reiterates: Buy
Price Target: $13
Current: $4.95
Upside: +162.63%
Achieve Life Sciences
Mar 25, 2026
Reiterates: Buy
Price Target: $12
Current: $3.20
Upside: +275.00%
Collegium Pharmaceutical
Mar 20, 2026
Reiterates: Buy
Price Target: $60
Current: $32.76
Upside: +83.15%
Pelthos Therapeutics
Mar 19, 2026
Reiterates: Buy
Price Target: $60
Current: $22.74
Upside: +163.85%
Eupraxia Pharmaceuticals
Mar 17, 2026
Maintains: Buy
Price Target: $12 → $11
Current: $6.77
Upside: +62.48%
Sagimet Biosciences
Mar 11, 2026
Reiterates: Buy
Price Target: $29
Current: $5.08
Upside: +470.87%
Trevi Therapeutics
Mar 9, 2026
Reiterates: Buy
Price Target: $21
Current: $13.10
Upside: +60.31%
Xeris Biopharma Holdings
Mar 2, 2026
Reiterates: Buy
Price Target: $10
Current: $5.87
Upside: +70.36%
MannKind
Feb 27, 2026
Maintains: Buy
Price Target: $11 → $8
Current: $2.57
Upside: +211.28%
Feb 11, 2026
Reiterates: Buy
Price Target: $13
Current: $4.10
Upside: +217.07%
Feb 10, 2026
Reiterates: Buy
Price Target: $9
Current: $1.40
Upside: +542.86%
Feb 10, 2026
Reiterates: Buy
Price Target: $20
Current: $13.43
Upside: +48.92%
Jan 23, 2026
Maintains: Buy
Price Target: $18 → $13
Current: $7.17
Upside: +81.31%
Jan 9, 2026
Reiterates: Buy
Price Target: $6
Current: $0.79
Upside: +660.07%
Jan 8, 2026
Maintains: Buy
Price Target: $20 → $40
Current: $10.98
Upside: +264.30%
Jan 6, 2026
Reiterates: Buy
Price Target: $8
Current: $1.61
Upside: +396.89%
Dec 3, 2025
Initiates: Buy
Price Target: $8
Current: $1.60
Upside: +400.00%
Sep 22, 2025
Initiates: Buy
Price Target: $10
Current: $1.58
Upside: +532.91%
Sep 17, 2025
Maintains: Buy
Price Target: $93 → $121
Current: $79.47
Upside: +52.26%
Aug 25, 2025
Reiterates: Buy
Price Target: $18
Current: $5.95
Upside: +202.52%
Aug 13, 2025
Reiterates: Buy
Price Target: $7
Current: $2.82
Upside: +148.23%
Jul 2, 2025
Initiates: Buy
Price Target: $26
Current: $9.68
Upside: +168.60%
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $0.95
Upside: +426.43%
Nov 14, 2024
Initiates: Buy
Price Target: $200
Current: $1.64
Upside: +12,095.12%
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $7.85
Upside: +103.82%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $7.02
Upside: +6,381.48%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $16.83
Upside: +250.56%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $190.94
Upside: -5.73%
Dec 5, 2022
Maintains: Overweight
Price Target: $300 → $220
Current: $2.48
Upside: +8,770.97%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $33.02
Upside: -3.09%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $0.80
Upside: +2,749,900.00%
Mar 5, 2020
Reiterates: Overweight
Price Target: $405 → $315
Current: $9.60
Upside: +3,181.25%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $9.26
Upside: +439.96%